HK1083500A1 - 2,7-Substituted indoles and their use as 5-ht6 modulators - Google Patents

2,7-Substituted indoles and their use as 5-ht6 modulators

Info

Publication number
HK1083500A1
HK1083500A1 HK06103482A HK06103482A HK1083500A1 HK 1083500 A1 HK1083500 A1 HK 1083500A1 HK 06103482 A HK06103482 A HK 06103482A HK 06103482 A HK06103482 A HK 06103482A HK 1083500 A1 HK1083500 A1 HK 1083500A1
Authority
HK
Hong Kong
Prior art keywords
modulators
substituted indoles
indoles
substituted
Prior art date
Application number
HK06103482A
Other languages
English (en)
Inventor
Ann Marie Madera
Robert James Weikert
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1083500A1 publication Critical patent/HK1083500A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK06103482A 2002-09-17 2006-03-20 2,7-Substituted indoles and their use as 5-ht6 modulators HK1083500A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41123902P 2002-09-17 2002-09-17
PCT/EP2003/010101 WO2004026830A1 (en) 2002-09-17 2003-09-11 2,7-substituted indoles and their use as 5-ht6 modulators

Publications (1)

Publication Number Publication Date
HK1083500A1 true HK1083500A1 (en) 2006-07-07

Family

ID=32030655

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103482A HK1083500A1 (en) 2002-09-17 2006-03-20 2,7-Substituted indoles and their use as 5-ht6 modulators

Country Status (29)

Country Link
US (1) US7247651B2 (ja)
EP (1) EP1587788B9 (ja)
JP (1) JP4327091B2 (ja)
KR (1) KR100686758B1 (ja)
CN (1) CN1314669C (ja)
AR (1) AR041255A1 (ja)
AT (1) ATE362469T1 (ja)
AU (1) AU2003273855B2 (ja)
BR (1) BR0314352A (ja)
CA (1) CA2496765A1 (ja)
DE (1) DE60313895T2 (ja)
DK (1) DK1587788T3 (ja)
ES (1) ES2287518T3 (ja)
GT (1) GT200300199A (ja)
HK (1) HK1083500A1 (ja)
HR (1) HRP20050229A2 (ja)
MX (1) MXPA05002696A (ja)
MY (1) MY138826A (ja)
NO (1) NO20050666L (ja)
NZ (1) NZ537982A (ja)
PA (1) PA8582201A1 (ja)
PE (1) PE20050054A1 (ja)
PL (1) PL376020A1 (ja)
PT (1) PT1587788E (ja)
RU (1) RU2327685C2 (ja)
TW (1) TWI249402B (ja)
UY (1) UY27980A1 (ja)
WO (1) WO2004026830A1 (ja)
ZA (1) ZA200501306B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2307919T3 (es) 2002-03-27 2008-12-01 Glaxo Group Limited Derivados de quinolina y su uso como ligandos de 5-ht6.
PT1558582E (pt) 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
RS50589B (sr) * 2003-12-23 2010-05-07 H. Lundbeck A/S. 2-(1h-indolilsulfanil)-benzil amin derivati kao ssri
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
ES2359725T3 (es) 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos.
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
US7629473B2 (en) * 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
BRPI0718776A2 (pt) * 2006-11-09 2013-12-03 Hoffmann La Roche Derivados de indol e benzofurano 2-carboxamida
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CN103288707B (zh) * 2013-05-28 2015-12-23 浙江大学 一种3-苯巯基吲哚衍生物的制备方法
US9663498B2 (en) 2013-12-20 2017-05-30 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
WO2016004882A1 (en) 2014-07-08 2016-01-14 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
KR20180064373A (ko) 2015-07-15 2018-06-14 엑소반트 사이언시즈 게엠베하 신경퇴행성 질환과 관련된 환각의 예방 및 치료에 유용한 5-ht2a 세로토닌 수용체의 조절자로서의 다이아릴 및 아릴헤테로아릴 우레아 유도체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9700693A (es) 1994-07-26 1997-04-30 Pfizer Derivados del 4-indol.
US6114532A (en) * 1998-02-03 2000-09-05 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals
EP0982304B1 (en) 1998-06-30 2002-10-02 Eli Lilly And Company Piperidine derivatives having effects on serotonin related systems
FR2788772B1 (fr) * 1999-01-26 2001-03-02 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
EP1401813B1 (en) * 2001-06-07 2007-02-07 F. Hoffman-la Roche AG New indole derivatives with 5-ht6 receptor affinity
CA2450245A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2003013510A1 (en) * 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
JP4754821B2 (ja) 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物

Also Published As

Publication number Publication date
NO20050666L (no) 2005-03-11
DK1587788T3 (da) 2007-09-24
ZA200501306B (en) 2006-05-31
NZ537982A (en) 2007-05-31
PL376020A1 (en) 2005-12-12
ES2287518T3 (es) 2007-12-16
MY138826A (en) 2009-07-31
US20040063724A1 (en) 2004-04-01
JP4327091B2 (ja) 2009-09-09
EP1587788A1 (en) 2005-10-26
PA8582201A1 (es) 2004-04-23
RU2327685C2 (ru) 2008-06-27
DE60313895D1 (de) 2007-06-28
ATE362469T1 (de) 2007-06-15
CA2496765A1 (en) 2004-04-01
UY27980A1 (es) 2004-03-31
TW200410685A (en) 2004-07-01
AR041255A1 (es) 2005-05-11
AU2003273855B2 (en) 2009-01-15
AU2003273855A1 (en) 2004-04-08
DE60313895T2 (de) 2008-01-17
HRP20050229A2 (hr) 2006-04-30
EP1587788B9 (en) 2007-10-24
JP2006503052A (ja) 2006-01-26
CN1314669C (zh) 2007-05-09
EP1587788B1 (en) 2007-05-16
GT200300199A (es) 2006-08-22
KR20050057357A (ko) 2005-06-16
PE20050054A1 (es) 2005-02-18
KR100686758B1 (ko) 2007-02-26
RU2005111587A (ru) 2005-11-20
PT1587788E (pt) 2007-08-20
CN1681782A (zh) 2005-10-12
TWI249402B (en) 2006-02-21
WO2004026830A1 (en) 2004-04-01
US7247651B2 (en) 2007-07-24
BR0314352A (pt) 2005-07-19
MXPA05002696A (es) 2005-05-05

Similar Documents

Publication Publication Date Title
HK1083500A1 (en) 2,7-Substituted indoles and their use as 5-ht6 modulators
HK1083497A1 (en) 2,4-Substituted indoles and their use as 5-ht6 modulators
SI2233483T1 (sl) Indolni ali benzimidazolni derivati za modulacijo IkapaB-kinaze in intermediati za njihovo pripravo
HK1080846A1 (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
PL377296A1 (pl) Pochodne 1,5-diarylo-pirolo-3-karboksyamidu oraz ich zastosowanie jako modulatorów receptora kannabinoidowego
ZA200406362B (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials.
HK1068610A1 (en) New indole derivatives with 5-ht6 receptor affinity
IL172894A0 (en) Indol-6-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
PL375111A1 (en) Novel substituted indoles
AU2003287160A1 (en) Substituted indoles and their use as hcv inhibitors
IL172891A0 (en) Indol-5-yl-sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
HK1073070A1 (en) Novel biomaterials, their preparation and use
EP1697322A4 (en) SUBSTITUTED TETRAHYDROCARBAZOL AND CYCLOPENTANOINDOL DERIVATIVES
AU2003303388A1 (en) Triptolide derivatives and their use
HK1081954A1 (en) Novel 1,4-diazabicycloalkane derivatives, their preparation and use
AU2003292508A1 (en) N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
HRP20031096A2 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators
MXPA03000644A (es) Nuevos derivados de indol y uso como medicamentos.
PL371365A1 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use as cdc25 phosphatase inhibitors
IL172750A0 (en) Indol-7 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators
TWI348382B (en) N-acetylglucosamine derivatives, and the use thereof
EP1517879A4 (en) AMINOALKYLPHENOLS AND METHODS OF USE AND MANUFACTURE
SI1587788T1 (sl) 2,7-substituirani indoli in njihova uporaba kot 5-ht6 modulatorji
AU2003303068A1 (en) Carbazole derivatives and their use as npy-5 antagonists
SI1506179T1 (sl) Derivati benzoksazina kot modulatorji 5-ht6 in njihova uporaba

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100911